NCT00413192View on ClinicalTrials.gov

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

February 28, 2013

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

E7389

1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.

Trial Locations (15)

13385

Marseille

15526

Bad Saarow

33076

Bordeaux

69008

Lyon

94805

Villejuif

BE 1000

Brussels

BE 3000

Leuven

DK 8000

Aarhus

DK 2730

Herlev

DE 01307

Dresden

DE 45122

Essen

DE 30625

Hanover

DE 68135

Mannheim

DE 72076

Tübingen

02 781

Warsaw

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT00413192 - E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter